Abbott Laboratories(ABT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 7:43 PM ET (Korea 10/24 08:43)
Full metrics table
| Index | S&P 500 | P/E | 38.29 | EPS (ttm) | 2.71 | Insider Own | 0.68% | Shs Outstand | 1.73B | Perf Week | -1.13% |
| Market Cap | 179.44B | Forward P/E | 17.43 | EPS next Y | 7.8% | Insider Trans | -3.21% | Shs Float | 1.72B | Perf Month | 2.6% |
| Enterprise Value | 207.10B | PEG | 2.14 | EPS next Q | 1.64 | Inst Own | 82.22% | Short Float | 0.79% | Perf Quarter | -0.76% |
| Income | 4.72B | P/S | 3.72 | EPS this Y | 7.14% | Inst Trans | -1.36% | Short Ratio | 1.51 | Perf Half Y | 13.79% |
| Sales | 48.23B | P/B | 3.51 | EPS next 5Y | 8.15% | ROA | 5.59% | Short Interest | 13.63M | Perf YTD | -17.23% |
| Book/sh | 29.54 | P/C | 32.03 | EPS past 3/5Y | -1.7% 8.23% | ROE | 10.63% | 52W High | -21.45% ($132.02) | Perf Year | -17.92% |
| Cash/sh | 3.24 | P/FCF | 22.93 | Sales past 3/5Y | 0.51% 5.08% | ROIC | 5.85% | 52W Low | 26.51% ($81.97) | Perf 3Y | 8.27% |
| Dividend Est. | $2.58 (2.49%) | EV/EBITDA | 18.65 | EPS Y/Y TTM | -61.33% | Gross Margin | 59.63% | Volatility(W/M) | 4.08% 2.65% | Perf 5Y | -18.17% |
| Dividend TTM | 2.52 | EV/Sales | 4.29 | Sales Y/Y TTM | 10% | Oper. Margin | 14.46% | ATR (14) | 2.87 | Perf 10Y | 156.05% |
| Dividend Ex-Date | 2026/10/15 | Quick Ratio | 0.97 | EPS Q/Q | -42.13% | Profit Margin | 9.8% | RSI (14) | 53.95 | Recom | 1.58 |
| Dividend Gr. 3/5Y | 7.72% 9.42% | Current Ratio | 1.38 | Sales Q/Q | 14.46% | SMA20 | 2.66% ($101.01) | Beta | 0.55 | Target Price | $119.2 |
| Payout | 64.54% | Debt/Eq | 0.64 | Earnings | 2026/10/21 | SMA50 | -1.4% ($105.17) | Rel Volume | 1.14 | Prev Close | $102.51 |
| Employees | 115000 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 0.03% 0.18% | SMA200 | 1.45% ($102.22) | Avg Volume(3M) | 9.05M | Price | $103.7 |
| IPO | 1937/3/1 | Option/Short | Yes/Yes | Trades | 65984 | Volume | 10,296,897 | Change | 1.16% |
A global diversified healthcare company operating medical devices, diagnostics, nutrition, and established pharmaceuticals businesses. Founded in 1888 and headquartered in the US, it holds a leading global position in diabetes care, cardiovascular medical devices, and diagnostics.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded about as much as usual. That is 114% of its average volume.
ABT earns at a steady pace
Of every $100 in sales, $14.46 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.1% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,865. Peers typically go for $1,594. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -18.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 2.49% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 82.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It is the largest in the industry
Based on market cap of $179B.
ABT#1 Abbott Laboratories $179B PER 38.3 
MDT#2 Medtronic Plc $122B PER 23.5 
SYK#3 Stryker Corp $118B PER 31.8 
BSX#4 Boston Scientific Corp $66B PER 18.5 
EW#5 Edwards Lifesciences Corp $51B PER 52.9 
FAQ
What kind of company is ABT?
ABT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ABT?
The market cap of ABT is approximately $179.4B, ranking 87 within its sector.
Does ABT pay dividends?
ABT has a dividend yield of approximately 2.49%, with an annual dividend of $2.58.
What is the P/E ratio of ABT?
ABT has a P/E ratio of approximately 38.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ABT?
ABT has recorded a 52-week high of $132.02 and a low of $81.97.
